Focused On-demand Library for mRNA export factor GLE1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q53GS7

UPID:

GLE1_HUMAN

Alternative names:

GLE1 RNA export mediator; GLE1-like protein; Nucleoporin GLE1

Alternative UPACC:

Q53GS7; O75458; Q53GT9; Q5VVU1; Q8NCP6; Q9UFL6

Background:

The mRNA export factor GLE1, also known as GLE1 RNA export mediator or Nucleoporin GLE1, plays a crucial role in cellular function by facilitating the export of mRNAs with poly(A) tails from the nucleus to the cytoplasm. This process is vital for the proper expression of genes and the functioning of the cell.

Therapeutic significance:

GLE1's involvement in lethal congenital contracture syndrome 1 and congenital arthrogryposis with anterior horn cell disease highlights its potential as a target for therapeutic intervention. Understanding the role of mRNA export factor GLE1 could open doors to potential therapeutic strategies for these devastating conditions.